Buyer-Directed Change Orders Sample Clauses

Buyer-Directed Change Orders. (a) Buyer shall have the authority to make discretionary changes to the scope of Work pursuant to a Change Order (each a “Buyer Discretionary Change”), subject to agreement on any equitable changes to, as applicable, the Guaranteed Substantial Completion Date or the Purchase Price (including any modifications to the Substantial Completion Payment Amount) resulting exclusively from such Buyer Discretionary Change; provided, however, that (i) the aggregate value of all new Work subject to such Change Orders for Buyer Discretionary Changes made by Buyer shall not exceed the greater of (A) Five Million Dollars ($5,000,000) and (B) seven and one-half percent (7.5%) of the Purchase Price (unless the Buyer Discretionary Change(s) are in connection with Remedying damage or loss to the Project or Project Assets after the Closing for which Buyer is responsible under this Agreement and which, after taking into account Section 13.4(a) (including clause (A)), requires a Buyer Discretionary Change, in which case the foregoing limitation shall not apply), and (ii) any dispute over any equitable change to, as applicable, the Guaranteed Substantial Completion Date or the Purchase Price (including any modifications to the Substantial Completion Payment Amount) due to a Buyer Discretionary Change shall be treated as provided in Section 8.2(d) and Section 8.6.
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
Buyer-Directed Change Orders. As part of the Purchase Price, Buyer shall pay Seller any direct cost increases (netted out against any direct cost reductions resulting from Buyer-Directed Change Orders) reasonably incurred by Developer as a result of Buyer-Directed Change Orders.
Sample 1

Related to Buyer-Directed Change Orders

  • Change Orders Any alteration or deviation from the Services mentioned or any other contractual specifications that result in a revision of this Agreement shall be executed and attached to this Agreement as a change order (“Change Order”).

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

  • Change Order (5) The Change Order is then submitted to the Project Manager who immediately processes the CO with OPC as required by Bulletin 3.5 and BGS’ Contracting Plan.

  • Seller’s Deliverables At the Closing, Seller shall deliver to Buyer:

  • Term SOFR Conforming Changes In connection with the use or administration of Term SOFR, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify the Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.

  • Approval Process Tenant shall notify Landlord whether it approves of the submitted working drawings within three business days after Landlord’s submission thereof. If Tenant disapproves of such working drawings, then Tenant shall notify Landlord thereof specifying in reasonable detail the reasons for such disapproval, in which case Landlord shall, within five business days after such notice, revise such working drawings in accordance with Tenant’s objections and submit the revised working drawings to Tenant for its review and approval. Tenant shall notify Landlord in writing whether it approves of the resubmitted working drawings within one business day after its receipt thereof. This process shall be repeated until the working drawings have been finally approved by Landlord and Tenant. If Tenant fails to notify Landlord that it disapproves of the initial working drawings within three business days (or, in the case of resubmitted working drawings, within one business day) after the submission thereof, then Tenant shall be deemed to have approved the working drawings in question. Any delay caused by Tenant’s unreasonable withholding of its consent or delay in giving its written approval as to such working drawings shall constitute a Tenant Delay Day (defined below). If the working drawings are not fully approved (or deemed approved) by both Landlord and Tenant by the 15th business day after the delivery of the initial draft thereof to Tenant, then each day after such time period that such working drawings are not fully approved (or deemed approved) by both Landlord and Tenant shall constitute a Tenant Delay Day.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Benchmark Replacement Conforming Changes In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.

  • Deliverables at Closing (a) At the Closing, Buyer shall deliver to the Company:

  • Purchasers Deliverables Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

Time is Money Join Law Insider Premium to draft better contracts faster.